Patrik Weder

The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network

Caroline Voskens, Simone M. Goldinger, Carmen Loquai et al. · PLoS ONE · 2013 · 470 citations · Full text

Medicine, Oncology, Pharmacology +16

Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44–GeparQuinto)

Gϋnter von Minckwitz, Gϋnter von Minckwitz, Sibylle Loibl et al. · Annals of Oncology · 2014 · 140 citations

Medicine, Oncology, Pharmacology +15

Re-irradiation with and without bevacizumab as salvage therapy for recurrent or progressive high-grade gliomas

Thomas Hundsberger, Detlef Brügge, Paul Martin Putora et al. · Journal of Neuro-Oncology · 2013 · 54 citations

Medicine, Oncology, Radiation Oncology +11

Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials

Silvia Höfer, Katarzyna Elandt, Richard Greil et al. · Acta Oncologica · 2011 · 45 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Phase I trial of the androgen receptor modulator CR1447 in breast cancer patients

Martin Zweifel, Beat Thürlimann, Salomé Riniker et al. · Endocrine Connections · 2017 · 13 citations · Full text

Medicine, Oncology, Pharmacology +15